Skip to content

BiPhasic Cartilage Repair Implant (BiCRI) IDE Clinical Trial - Taiwan

A Prospective, Multi-Center, Randomized Clinical Trial Comparing the Biphasic Cartilage Repair Implant to Marrow Stimulation in the Treatment of Focal Chondral and Osteochondral Lesions of the Knee

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01477008
Enrollment
92
Registered
2011-11-22
Start date
2011-10-31
Completion date
2019-08-31
Last updated
2022-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chondral or Osteochondral Lesion of Lateral Femoral Condyle, Chondral or Osteochondral Lesion of Medial Femoral Condyle, Chondral or Osteochondral Lesion of Trochlea

Keywords

Knee, Cartilage repair, Cartilage regeneration, Chondral, Osteochondral, Biphasic scaffold, Medical device, Autologous, Synthetic, Medial condyle, Lateral condyle, Trochlea

Brief summary

The purpose of this trial is to evaluate the safety and effectiveness of the Biphasic Cartilage Repair Implant (BiCRI) compared to marrow stimulation in the treatment of chondral and osteochondral lesions located on the medial femoral condyle, lateral femoral condyle, or trochlea of the knee. The hypothesis is that the BiCRI provides an improvement in pain and function as compared to baseline, that is no worse than marrow stimulation at 1 year.

Interventions

DEVICEBiPhasic Cartilage Repair Implant

1 or 2 BiCRI devices, depending on lesion size

PROCEDUREMarrow Stimulation

Microfracture or Subchondral Drilling

Sponsors

BioGend Therapeutics Co.Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
No minimum to 55 Years
Healthy volunteers
No

Inclusion criteria

1. Male or female presenting with a single, symptomatic chondral or osteochondral lesion of the medial or lateral femoral condyles or the trochlea requiring primary surgical intervention 2. Skeletally mature (epiphyses are confirmed to be closed on x-ray) 3. ICRS grade 3-4 lesion, Outerbridge grade 4, or OCD grades 3-4 4. Lesion size requires no more than 2 implants (assuming patient were to be randomized to the treatment group). Lesion size will be assessed at the time of the study procedure for all subjects. If the size of the lesion is appropriate for 1 or 2 implants the patient will be randomized. If the lesion is found to be too large the patient will not be included in the trial, but will be treated according to standard of care. Lesion sizes that are considered appropriate include the following: * Lesion is 3mm x 3mm or larger and can be completely covered by the small (12.5mm diameter) sizer (excluding small fissures). This lesion should be treated with 1 implant. or * Lesion is 3mm x 3mm or larger and cannot be covered by the small sizer, but can be completely covered by the large (oval shaped) sizer (excluding small fissures). This lesion should be treated with 2 implants. 5. Willing and able to refrain from taking pain medications (including: narcotic and non-steroidal anti-inflammatory drugs) for 7 days prior to the baseline preoperative visit and for 7 days prior to the 12-month postoperative visit (i.e., a wash out period) 6. Willing and able to return for follow-up over a one year post-operative period 7. Willing and able to comply with all postoperative guidelines

Exclusion criteria

1. ≥ 55 years old 2. Lesions \> grade II on the articular surface of the tibia or patella 3. Kissing lesions (defined as an opposing lesion \> grade II on the surface of the tibia or patella). Lesion ≤ grade II on opposing surface would be acceptable. 4. Prior surgical treatment of the lesion 5. Lesion would require more than 2 implants (assuming patient were to be randomized to the treatment group). Lesion sizes that are not considered appropriate include the following: * Lesion is smaller than 3mm x 3mm * Lesion cannot be completely covered by the large sizer 6. Lesion will require bone grafting 7. Rheumatoid arthritis and other inflammatory arthritis 8. Concomitant comorbidities, such as: * ACL instability that will not be corrected before or during the study procedure (ACL instability defined as the presence of a positive pivot shift test) * Significant knee instability that will not be corrected before or during the study procedure * Significant malalignment (varus or valgus deformity, patellar malalignment) that will not be corrected before or during the study procedure. Significant malalignment defined as: * Any joint space narrowing as compared to the same compartment in the contralateral knee. * Mechanical axis alignment outside the tibial spines. * Patellofemoral subluxation on sunrise view. * History of patellar dislocation or subluxation. * Severe meniscal damage (Severe meniscal damage defined as \> 50% of the meniscus missing or a radial tear extending to the meniscal-synovial junction) * Knee stiffness, defined as: * Flexion contracture \>10° * Flexion degree \< 115° 9. Body Mass Index (BMI) \> 35.0 10. Local or systemic infection, not including asymptomatic urinary tract infection if treated with antibiotics preoperatively 11. Pregnancy or breast feeding 12. Prisoner 13. Patient is involved in a personal litigation (e.g. Worker's Compensation lawsuit) that relates to their knee surgery 14. Patient is actively participating in another medical device, drug, or biologic investigation (active defined as within the last 30 days) 15. Patient otherwise meets the study criteria but refuses to consent in writing to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
IKDC-2000 Subjective Knee Evaluation12 monthsSubjective evaluation of knee pain and function (will be captured at preop and each postop visit through 12 months)

Secondary

MeasureTime frameDescription
IKDC-2000 Current Health Assessment FormPreop, 6 weeks, 3 months, 6 months, and 12 monthsSubjective evaluation of quality of life (QOL) and activities of daily living (ADL)
Knee Injury and Osteoarthritis Outcome Score (KOOS)Preop, 6 weeks, 3 months, 6 months, and 12 monthsA subjective instrument to assess the subject's opinion about their knee and associated problems
Pain (VAS): sitting, standing, and squattingPreop, 6 weeks, 3 months, 6 months, and 12 monthsSubjective evaluation of pain during routine activities
IKDC-2000 Knee Examination FormPreop, 6 weeks, 3 months, 6 months, and 12 monthsObjective evaluation of knee pain and function
RadiographsPreop, immediate postop, 6 weeks, 3 months, 6 months, 12 monthsNot all views taken at each time frame. * Weight bearing full extension AP view (both knees) * Rosenberg view (45 degree PA flexion weight bearing, both knees) * Lateral view of involved knee * Sunrise (skyline) view of involved knee
Adverse EventsTreatment through 12 monthsDocumentation of all adverse events from treatment through the end of the study.
Arthroscopy with biopsy12 monthsArthroscopic second look to visualize the repair site. Biopsy of the cartilage and bone region of the treated site. Only performed on patients who agree to second procedure.
Magnetic Resonance Imagining (MRI)Preop and 12 monthsMRI to evaluate cartilage and bone condition

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026